KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Profit After Tax: 2009-2024

Historic Profit After Tax for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $4.4 billion.

  • Regeneron Pharmaceuticals' Profit After Tax rose 8.91% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 billion, marking a year-over-year decrease of 1.64%. This contributed to the annual value of $4.4 billion for FY2024, which is 11.61% up from last year.
  • As of FY2024, Regeneron Pharmaceuticals' Profit After Tax stood at $4.4 billion, which was up 11.61% from $4.0 billion recorded in FY2023.
  • In the past 5 years, Regeneron Pharmaceuticals' Profit After Tax ranged from a high of $8.1 billion in FY2021 and a low of $3.5 billion during FY2020.
  • Its 3-year average for Profit After Tax is $4.2 billion, with a median of $4.3 billion in 2022.
  • Per our database at Business Quant, Regeneron Pharmaceuticals' Profit After Tax surged by 129.86% in 2021 and then crashed by 46.28% in 2022.
  • Yearly analysis of 5 years shows Regeneron Pharmaceuticals' Profit After Tax stood at $3.5 billion in 2020, then surged by 129.86% to $8.1 billion in 2021, then plummeted by 46.28% to $4.3 billion in 2022, then fell by 8.87% to $4.0 billion in 2023, then rose by 11.61% to $4.4 billion in 2024.